If you could bring in former Amgen CEO Kevin Sharer as a consultant, what would he say?
Amgen's new CEO scored a big raise when he was promoted last year. Robert Bradway took over from ex-chief Kevin Sharer at the end of May, and by year's end, he had racked up $13.57 million in compensation for the year, almost twice what he made in 2011 as president and COO. And his predecessor's pay dropped by half, knocking him off our list of highest-paid biopharma executives.
We know how pharma CEO pay stacked up within the industry. But how did pharma's 2011 compensation packages compare with those in other industries?
Amgen CEO Kevin Sharer tells McKinsey that he was "an awful listener" for years, until he cultivated the humility to stop "telling" 90% of the time.
Stock options and deferred compensation have built up a comfortable $49 million nest egg for retiring Amgen ($AMGN) CEO Kevin Sharer.
Roger Perlmutter appears to have no plans to slow down after ending his 11-year tenure as Amgen's ($AMGN) R&D chief last month after a major leadership shakeup announced late last year at the...
Xconomy's Luke Timmerman assesses Amgen CEO Kevin Sharer's tenure this morning, giving him a gentleman's "C" for leadership, new product development, vision and other key factors. As Timmerman notes,
Facing investors unhappy over an unimpressive stock price and its R&D wing being pared down to reduce the bite it takes out of revenue, Amgen announced yesterday that both its CEO and R&D
With investors chronically unhappy over an unimpressive stock price and the R&D wing being sliced back to reduce the bite it takes out of revenue, Amgen announced yesterday that both its CEO and
Has Amgen ($AMGN) proven itself a card-carrying member of Big Pharma? Signs point in that direction, the Pacific Coast Business Times says. After all, the company not only announced its first